.After raising $170 million back in February, metabolic disease-focused BioAge Labs has actually filed to debut on the public market.The Eli Lilly-partnered biotech want to detail on the Nasdaq under the symbolic representation "BIOA," according to papers filed along with the Securities and Exchange Compensation. The provider has actually certainly not openly discussed an assumed monetary volume for the offering.The clinical-stage business touts lead candidate azelaprag, a by mouth provided tiny molecule slated to enter stage 2 screening in combination along with semaglutide-- offered through Novo Nordisk under brand Wegovy for fat loss-- in the 1st one-half of next year. Semaglutide is actually also marketed as Ozempic and Rybelsus through Novo for diabetes.
Apelin receptor agonist azelaprag is actually designed to incorporate well with GLP-1 drugs, boosting weight management while maintaining muscular tissue mass. The investigational medicine was actually located to become well-tolerated amongst 265 people all over 8 phase 1 tests, according to BioAge.Earlier, BioAge achieved the support of Lilly to operate a trial incorporating azelaprag with the Huge Pharma's GLP-1/ GIP receptor agonist tirzepatide, which is marketed for diabetes mellitus as Mounjaro and Zepbound for weight loss. The partners are currently administering a period 2 trial of azelaprag as well as tirzepatide, with topline outcomes expected in the 3rd fourth of 2025.The biotech is actually likewise preparing a the hormone insulin sensitivity proof-of-concept test analyzing azelaprag as a monotherapy in the initial one-half of following year to support potential indicator growth. Moreover, the business plans to talk to the FDA for approval in the 2nd fifty percent of 2025 to launch human screening for an NLRP3 inhibitor targeting metabolic ailments as well as neuroinflammation.BioAge's expected move to the general public market follows a small uptick in intended biotech IPOs from Bicara Therapeutics and also Zenas Biopharma. Zooming out, the latest IPO landscape is actually a "blended image," with high quality firms still debuting on everyone markets, just in decreased numbers, depending on to PitchBook.